[(2R)-3-(2-methoxy-10H-phenothiazin-10-yl)-2-methylpropyl]dimethylamine

• ChemBase ID: 1213
• Molecular Formular: C19H24N2OS
• Molecular Mass: 328.47166
• Monoisotopic Mass: 328.1609344
• SMILES: c1ccc2c(c1)N(c1c(S2)ccc(c1)OC)C[C@@H](CN(C)C)C
• Canonical SMILES: COc1ccc2c(c1)N(C[C@@H](CN(C)C)C)c1c(S2)cccc1
• InChI: InChI=1S/C19H24N2OS/c1-14(12-20(2)3)13-21-16-7-5-6-8-18(16)23-19-10-9-15(22-4)11-17(19)21/h5-11,14H,12-13H2,1-4H3/t14-/m1/s1
• InChIKey: VRQVVMDWGGWHTJ-CQSZACIVSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: [(2R)-3-(2-methoxy-10H-phenothiazin-10-yl)-2-methylpropyl]dimethylamine
• IUPAC Traditional name: methotrimeprazine
• Brand Name: Nosinan; Nozinan; Levoprome; Neurocil; Neozine
• Synonyms: Levomepromazine; Methotrimeprazine; Levomepromazine

Database IDs

• CAS Number: 60-99-1
• PubChem SID: 160964673; 46507223
• PubChem CID: 72287
• CHEBI ID: 6838
• ATC CODE: N05AA02
• CHEMBL: 1764
• Chemspider ID: 65239
• DrugBank ID: DB01403
• KEGG ID: D00403
• Unique Ingredient Identifier: 9G0LAW7ATQ
• Wikipedia Title: Levomepromazine

CALCULATED PROPERTIES

JChem

• H Acceptors: 3
• H Donor: 0
• LogD (pH = 5.5): 0.89110804
• LogD (pH = 7.4): 2.2412717
• Log P: 4.252608
• Molar Refractivity: 99.8311 cm^3
• Polarizability: 38.484814 Å^3
• Polar Surface Area: 15.71 Å^2
• Rotatable Bonds: 5
• Lipinski's Rule of Five: true

ALOGPS 2.1

• Log P: 4.84
• LOG S: -4.8
• Solubility (Water): 5.25e-03 g/l

PROPERTIES

Physical Property

• Hydrophobicity(logP): 4.68 [HANSCH,C ET AL. (1995)]

Pharmacology Properties

• Admin Routes: Oral, seldom intramuscular
• Bioavailability: approx. 50 to 60%
• Excretion: In feces and urine (metabolites), unchanged drug only 1%
• Half Life: ~ 20 hours
• Metabolism: Hepatic
• Legal Status: no (US)
• Pregnancy Category: Only if clearly needed

DETAILS

DrugBank - DB01403

• Drug Groups: approved
• Description: A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)
• Indication: For the treatment of psychosis, particular those of schizophrenia, and manic phases of bipolar disorder.
• Pharmacology: Methotrimeprazine is a phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)
• Toxicity: Symptoms of overdose include convulsions, spastic movements, and coma.
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic. Methotrimeprazine is metabolized in the liver and degraded to a sulfoxid-, a glucuronid- and a demethyl-moiety.
• Absorption: Methotrimeprazine has an incomplete oral bioavailability, because it undergoes considerable first-pass-metabolism in the liver. Oral bioavailability is approximately 50 to 60%.
• Half Life: Approximately 20 hours.
• References: [Link]
• External Links: Wikipedia

REFERENCES

• Link